anti-Bcl-xL oligonucleotides (Berne/Irvine)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Nameanti-Bcl-xL oligonucleotides (Berne/Irvine)
Drug Alias Nameantisense oncogene inhibitors (Berne/Irvine)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionOncogene proteins inhibitorsApoptosis regulator Bcl-X inhibitors
TargetsApoptosis regulator Bcl-XOncogene proteins
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Bern
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of California IrvineUniversity Of Bern
Active IndicationsN/A
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A